AP NEWS

Global Hepatitis B Therapeutics Market Forecast (2018-2022) with Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead, GlaxoSmithKline, and Merck Sharp & Dohme Leading the Competition - ResearchAndMarkets.com

January 2, 2019

DUBLIN--(BUSINESS WIRE)--Jan 2, 2019--The “Global Hepatitis B Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The global hepatitis B therapeutics market is fragmented, as many pharmaceutical companies are developing drugs for the treatments of hepatitis B. Also, several companies are forming collaborations to increase their research toward the hepatitis B drug development.

These types of strategic collaboration between the pharmaceutical companies will propel the hepatitis B therapeutics development and lead to increase the growth of the market during our forecast period. This will boost the growth of the hepatitis B therapeutics market at a CAGR of over 2% during the forecast period.

Increasing prevalence of hepatitis B in infants

The increase in the prevalence of hepatitis B in infants, the companies are developing various drugs against hepatitis B virus. This leads to an increase in the global market during the forecast period.

Low accessibility due to high cost of hepatitis B treatment

One of the major problems from the treatment of hepatitis B is that not all the approved drugs are accessible to people and some are not affordable. Therefore, low accessibility due to the high cost of hepatitis B treatment is one the biggest challenges for the goal aiming to eliminate hepatitis B during our forecast period.

Key Players

Bristol-Myers Squibb F. Hoffmann-La Roche Gilead GlaxoSmithKline Merck Sharp & Dohme

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 05: MARKET SIZING

Market definition Market sizing 2017 Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY APPLICATION

Segmentation by application Comparison by application Drugs - Market size and forecast 2017-2022 Vaccines - Market size and forecast 2017-2022 Market opportunity by application

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison Americas - Market size and forecast 2017-2022 EMEA - Market size and forecast 2017-2022 APAC - Market size and forecast 2017-2022 Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

Strategic alliances Strong pipeline New technological advancements

PART 14: VENDOR LANDSCAPE

Overview Landscape disruption

PART 15: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors Bristol-Myers Squibb F. Hoffmann-La Roche Gilead GlaxoSmithKline Merck Sharp & Dohme

For more information about this report visit https://www.researchandmarkets.com/research/dcgndb/global_hepatitis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190102005376/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs,Liver and Kidney Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/02/2019 10:12 AM/DISC: 01/02/2019 10:12 AM

http://www.businesswire.com/news/home/20190102005376/en

AP RADIO
Update hourly